Deuterated Organic Compounds and Uses Thereof
Summary
The USPTO granted Patent US12606523B2 to Engrail Therapeutics, Inc. covering deuterated organic compounds of Formula I useful for modulating dopamine neurotransmission and treating disorders such as schizophrenia and depression. The patent includes 17 claims encompassing the compounds, processes for their preparation, pharmaceutical compositions, and methods of treatment. Inventors include Krishna Vadodaria, Kimberly Vanover, Jordi Serrats, Vikram Sudarsan, and David Garvey.
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO granted Patent US12606523B2 to Engrail Therapeutics, Inc. for deuterated organic compounds of Formula I useful in modulating dopamine neurotransmission and treating schizophrenia and depression. The patent encompasses 17 claims including the compounds themselves, pharmaceutical compositions containing them, and methods of treatment using them. The filing date was July 3, 2024, under Application No. 18763819.
Pharmaceutical companies developing central nervous system therapeutics may need to review this patent to assess potential overlap with their own research programs or licensing needs. The granted claims provide Engrail Therapeutics with exclusive rights to the specified compounds and their therapeutic applications in the United States.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Deuterated organic compounds and uses thereof
Grant US12606523B2 Kind: B2 Apr 21, 2026
Assignee
ENGRAIL THERAPEUTICS, INC.
Inventors
Krishna Vadodaria, Kimberly Vanover, Jordi Serrats, Vikram Sudarsan, David Garvey
Abstract
Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
CPC Classifications
C07D 207/14
Filing Date
2024-07-03
Application No.
18763819
Claims
17
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.